Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
NCT ID: NCT04575844
Last Updated: 2025-04-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE4
Total Enrollment
80 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-11-01
Study Completion Date
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and skeletal muscle microvascular blood volume, improves vascular function of the conduit vessels, and enhances insulin's metabolic action in humans with Metabolic Syndrome. Subjects will be randomized to one of the 4 groups: control, exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 24 weeks of intervention.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
NCT03883412
Type2 Diabetes
RECRUITING
PHASE4
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
NCT05478707
Diabetes Mellitus, Type 1
Endothelial Dysfunction
SUSPENDED
PHASE2
The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes
NCT01455441
Type 2 Diabetes
COMPLETED
PHASE4
The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes
NCT03426085
Autonomic Nervous System Diseases
Sweat Gland Diseases
Diabetic Neuropathy With Neurologic Complication
UNKNOWN
PHASE2
Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients
NCT02655770
Diabetes Mellitus Type 2
Diastolic Dysfunction
Cardiac MRI
+1 more
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Our hypothesis is that sustained activation of the GLP-1 receptor with Liraglutide and exercise training each will enhance microvascular insulin responses and angiogenesis in both cardiac and skeletal muscle to increase muscle insulin delivery and action and the combination of both is more effective than either alone in adults with metabolic syndrome.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Metabolic Syndrome
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
FACTORIAL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exercise Alone
24 weeks of treatment
Group Type
EXPERIMENTAL
Exercise training
Intervention Type
OTHER
24 weeks of Exercise training
Liraglutide Alone
24 weeks of treatment
Group Type
EXPERIMENTAL
Liraglutide
Intervention Type
DRUG
24 weeks of Liraglutide
Exercise + Liraglutide
24 weeks f treatment
Group Type
EXPERIMENTAL
Liraglutide + Exercise training
Intervention Type
DRUG
24 weeks of Liraglutide + Exercise training
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Liraglutide
24 weeks of Liraglutide
Intervention Type
DRUG
Exercise training
24 weeks of Exercise training
Intervention Type
OTHER
Liraglutide + Exercise training
24 weeks of Liraglutide + Exercise training
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female ≥21 and ≤60 years old.
* Body mass index \>25 and ≤35 kg/m2 and is weight stable (\<5 kg weight change in the past 6 months). BMI is limited to ≤35 kg/m2 for easier vascular access and cardiac imaging.
* Meet 3 of 5 National Cholesterol Education Program Adult Treatment Panel III Metabolic Syndrome criteria:
* Increased waist circumference (≥102 cm in men; ≥88 cm in women)
* Elevated triglycerides (≥150 mg/dl)
* Reduced HDL-cholesterol (\<40mg/dl in men, \<50 mg/dl in women)
* High blood pressure (≥130 mmHg systolic or ≥85mmHg diastolic)
* Elevated fasting glucose (≥100 mg/dl)
* Subject may participate if on the following drugs, provided the drug doses have been stable for at least 3 months.
* Ace inhibitor
* ARB
* HMG CoA reductase inhibitor
* Beta blocker
* Calcium channel blockers
* Alpha-adrenergic antagonist
* Statin
* Body mass index \>25 and ≤35 kg/m2 and is weight stable (\<5 kg weight change in the past 6 months). BMI is limited to ≤35 kg/m2 for easier vascular access and cardiac imaging.
* Meet 3 of 5 National Cholesterol Education Program Adult Treatment Panel III Metabolic Syndrome criteria:
* Increased waist circumference (≥102 cm in men; ≥88 cm in women)
* Elevated triglycerides (≥150 mg/dl)
* Reduced HDL-cholesterol (\<40mg/dl in men, \<50 mg/dl in women)
* High blood pressure (≥130 mmHg systolic or ≥85mmHg diastolic)
* Elevated fasting glucose (≥100 mg/dl)
* Subject may participate if on the following drugs, provided the drug doses have been stable for at least 3 months.
* Ace inhibitor
* ARB
* HMG CoA reductase inhibitor
* Beta blocker
* Calcium channel blockers
* Alpha-adrenergic antagonist
* Statin
Exclusion Criteria
* A diagnosis of any type of diabetes or history of diabetes medication use
* Recently active (\>20 min of moderate/high intensity exercise, 2 times/week)
* Subjects who are smokers or who have quit smoking \<5 years
* Subjects with hypertriglyceridemia (\>400 mg/dl) or hypercholesterolemia (\>260 mg/dl)
* Subjects with BP\>160/90
* Subjects with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or malignancy
* Pregnant (as evidenced by positive pregnancy test) or nursing women
* Subjects with contraindications to participation in an exercise training program
* Allergic to perflutren
* A prior use of Liraglutide
* Recently active (\>20 min of moderate/high intensity exercise, 2 times/week)
* Subjects who are smokers or who have quit smoking \<5 years
* Subjects with hypertriglyceridemia (\>400 mg/dl) or hypercholesterolemia (\>260 mg/dl)
* Subjects with BP\>160/90
* Subjects with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or malignancy
* Pregnant (as evidenced by positive pregnancy test) or nursing women
* Subjects with contraindications to participation in an exercise training program
* Allergic to perflutren
* A prior use of Liraglutide
Minimum Eligible Age
21 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Sponsor Role
collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Sponsor Role
collaborator
University of Virginia
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhenqi Liu
Professor, Division of Endocrinology and Metabolism
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhenqi Liu, MD
Role: PRINCIPAL_INVESTIGATOR
Division of Endocrinology and Metabolism, University of Virginia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Virginia
Charlottesville, Virginia, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjoth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23.
Reference Type
BACKGROUND
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
Reference Type
BACKGROUND
Barrett EJ, Wang H, Upchurch CT, Liu Z. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. Am J Physiol Endocrinol Metab. 2011 Aug;301(2):E252-63. doi: 10.1152/ajpendo.00186.2011. Epub 2011 May 24.
Reference Type
BACKGROUND
Vincent MA, Clerk LH, Lindner JR, Klibanov AL, Clark MG, Rattigan S, Barrett EJ. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes. 2004 Jun;53(6):1418-23. doi: 10.2337/diabetes.53.6.1418.
Reference Type
BACKGROUND
Eggleston EM, Jahn LA, Barrett EJ. Hyperinsulinemia rapidly increases human muscle microvascular perfusion but fails to increase muscle insulin clearance: evidence that a saturable process mediates muscle insulin uptake. Diabetes. 2007 Dec;56(12):2958-63. doi: 10.2337/db07-0670. Epub 2007 Aug 24.
Reference Type
BACKGROUND
Chai W, Wang W, Liu J, Barrett EJ, Carey RM, Cao W, Liu Z. Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use. Hypertension. 2010 Feb;55(2):523-30. doi: 10.1161/HYPERTENSIONAHA.109.145409. Epub 2009 Dec 7.
Reference Type
BACKGROUND
Liu Z, Liu J, Jahn LA, Fowler DE, Barrett EJ. Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvasculature. J Clin Endocrinol Metab. 2009 Sep;94(9):3543-9. doi: 10.1210/jc.2009-0027. Epub 2009 Jun 30.
Reference Type
BACKGROUND
Liu J, Jahn LA, Fowler DE, Barrett EJ, Cao W, Liu Z. Free fatty acids induce insulin resistance in both cardiac and skeletal muscle microvasculature in humans. J Clin Endocrinol Metab. 2011 Feb;96(2):438-46. doi: 10.1210/jc.2010-1174. Epub 2010 Nov 3.
Reference Type
BACKGROUND
Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E123-9. doi: 10.1152/ajpendo.00021.2003.
Reference Type
BACKGROUND
Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes. 2006 May;55(5):1436-42. doi: 10.2337/db05-1373.
Reference Type
BACKGROUND
Youd JM, Rattigan S, Clark MG. Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-alpha. Diabetes. 2000 Nov;49(11):1904-9. doi: 10.2337/diabetes.49.11.1904.
Reference Type
BACKGROUND
Liu Z. The vascular endothelium in diabetes and its potential as a therapeutic target. Rev Endocr Metab Disord. 2013 Mar;14(1):1-3. doi: 10.1007/s11154-013-9238-8. No abstract available.
Reference Type
BACKGROUND
Gavin TP, Stallings HW 3rd, Zwetsloot KA, Westerkamp LM, Ryan NA, Moore RA, Pofahl WE, Hickner RC. Lower capillary density but no difference in VEGF expression in obese vs. lean young skeletal muscle in humans. J Appl Physiol (1985). 2005 Jan;98(1):315-21. doi: 10.1152/japplphysiol.00353.2004. Epub 2004 Aug 6.
Reference Type
BACKGROUND
Lillioja S, Young AA, Culter CL, Ivy JL, Abbott WG, Zawadzki JK, Yki-Jarvinen H, Christin L, Secomb TW, Bogardus C. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest. 1987 Aug;80(2):415-24. doi: 10.1172/JCI113088.
Reference Type
BACKGROUND
Solomon TP, Haus JM, Li Y, Kirwan JP. Progressive hyperglycemia across the glucose tolerance continuum in older obese adults is related to skeletal muscle capillarization and nitric oxide bioavailability. J Clin Endocrinol Metab. 2011 May;96(5):1377-84. doi: 10.1210/jc.2010-2069. Epub 2011 Feb 2.
Reference Type
BACKGROUND
Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006 May;7(5):359-71. doi: 10.1038/nrm1911.
Reference Type
BACKGROUND
Tang K, Breen EC, Gerber HP, Ferrara NM, Wagner PD. Capillary regression in vascular endothelial growth factor-deficient skeletal muscle. Physiol Genomics. 2004 Jun 17;18(1):63-9. doi: 10.1152/physiolgenomics.00023.2004. Epub 2004 Jun 17.
Reference Type
BACKGROUND
Bonner JS, Lantier L, Hasenour CM, James FD, Bracy DP, Wasserman DH. Muscle-specific vascular endothelial growth factor deletion induces muscle capillary rarefaction creating muscle insulin resistance. Diabetes. 2013 Feb;62(2):572-80. doi: 10.2337/db12-0354. Epub 2012 Sep 21.
Reference Type
BACKGROUND
Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res. 2007 Oct 26;101(9):948-56. doi: 10.1161/CIRCRESAHA.107.160630. Epub 2007 Sep 6.
Reference Type
BACKGROUND
Roque FR, Hernanz R, Salaices M, Briones AM. Exercise training and cardiometabolic diseases: focus on the vascular system. Curr Hypertens Rep. 2013 Jun;15(3):204-14. doi: 10.1007/s11906-013-0336-5.
Reference Type
BACKGROUND
Castorena CM, Arias EB, Sharma N, Cartee GD. Postexercise improvement in insulin-stimulated glucose uptake occurs concomitant with greater AS160 phosphorylation in muscle from normal and insulin-resistant rats. Diabetes. 2014 Jul;63(7):2297-308. doi: 10.2337/db13-1686. Epub 2014 Mar 7.
Reference Type
BACKGROUND
Vincent MA, Clerk LH, Lindner JR, Price WJ, Jahn LA, Leong-Poi H, Barrett EJ. Mixed meal and light exercise each recruit muscle capillaries in healthy humans. Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1191-7. doi: 10.1152/ajpendo.00497.2005.
Reference Type
BACKGROUND
Inyard AC, Clerk LH, Vincent MA, Barrett EJ. Contraction stimulates nitric oxide independent microvascular recruitment and increases muscle insulin uptake. Diabetes. 2007 Sep;56(9):2194-200. doi: 10.2337/db07-0020. Epub 2007 Jun 11.
Reference Type
BACKGROUND
Richter EA, Hargreaves M. Exercise, GLUT4, and skeletal muscle glucose uptake. Physiol Rev. 2013 Jul;93(3):993-1017. doi: 10.1152/physrev.00038.2012.
Reference Type
BACKGROUND
Wheatley CM, Rattigan S, Richards SM, Barrett EJ, Clark MG. Skeletal muscle contraction stimulates capillary recruitment and glucose uptake in insulin-resistant obese Zucker rats. Am J Physiol Endocrinol Metab. 2004 Oct;287(4):E804-9. doi: 10.1152/ajpendo.00077.2004. Epub 2004 Jun 22.
Reference Type
BACKGROUND
Hoier B, Hellsten Y. Exercise-induced capillary growth in human skeletal muscle and the dynamics of VEGF. Microcirculation. 2014 May;21(4):301-14. doi: 10.1111/micc.12117.
Reference Type
BACKGROUND
Olfert IM, Howlett RA, Tang K, Dalton ND, Gu Y, Peterson KL, Wagner PD, Breen EC. Muscle-specific VEGF deficiency greatly reduces exercise endurance in mice. J Physiol. 2009 Apr 15;587(Pt 8):1755-67. doi: 10.1113/jphysiol.2008.164384. Epub 2009 Feb 23.
Reference Type
BACKGROUND
Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 2007 Nov;293(5):E1289-95. doi: 10.1152/ajpendo.00373.2007. Epub 2007 Aug 21.
Reference Type
BACKGROUND
Aronis KN, Chamberland JP, Mantzoros CS. GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism. 2013 Sep;62(9):1279-86. doi: 10.1016/j.metabol.2013.04.010. Epub 2013 May 14.
Reference Type
BACKGROUND
Jayaweera AR, Wei K, Coggins M, Bin JP, Goodman C, Kaul S. Role of capillaries in determining CBF reserve: new insights using myocardial contrast echocardiography. Am J Physiol. 1999 Dec;277(6):H2363-72. doi: 10.1152/ajpheart.1999.277.6.H2363.
Reference Type
BACKGROUND
Laine H, Nuutila P, Luotolahti M, Meyer C, Elomaa T, Koskinen P, Ronnemaa T, Knuuti J. Insulin-induced increment of coronary flow reserve is not abolished by dexamethasone in healthy young men. J Clin Endocrinol Metab. 2000 May;85(5):1868-73. doi: 10.1210/jcem.85.5.6597.
Reference Type
BACKGROUND
Laine H, Sundell J, Nuutila P, Raitakari OT, Luotolahti M, Ronnemaa T, Elomaa T, Koskinen P, Knuuti J. Insulin induced increase in coronary flow reserve is abolished by dexamethasone in young men with uncomplicated type 1 diabetes. Heart. 2004 Mar;90(3):270-6. doi: 10.1136/hrt.2003.013722.
Reference Type
BACKGROUND
Sundell J, Nuutila P, Laine H, Luotolahti M, Kalliokoski K, Raitakari O, Knuuti J. Dose-dependent vasodilating effects of insulin on adenosine-stimulated myocardial blood flow. Diabetes. 2002 Apr;51(4):1125-30. doi: 10.2337/diabetes.51.4.1125.
Reference Type
BACKGROUND
Sundell J, Laine H, Nuutila P, Ronnemaa T, Luotolahti M, Raitakari O, Knuuti J. The effects of insulin and short-term hyperglycaemia on myocardial blood flow in young men with uncomplicated Type I diabetes. Diabetologia. 2002 Jun;45(6):775-82. doi: 10.1007/s00125-002-0819-4. Epub 2002 Apr 25.
Reference Type
BACKGROUND
Chai W, Liu J, Jahn LA, Fowler DE, Barrett EJ, Liu Z. Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans. Diabetes Care. 2011 Jul;34(7):1634-8. doi: 10.2337/dc10-2345. Epub 2011 May 26.
Reference Type
BACKGROUND
Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006 Jun;317(3):1106-13. doi: 10.1124/jpet.106.100982. Epub 2006 Feb 17.
Reference Type
BACKGROUND
Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005 Jan;54(1):146-51. doi: 10.2337/diabetes.54.1.146.
Reference Type
BACKGROUND
Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004 Mar 2;109(8):962-5. doi: 10.1161/01.CIR.0000120505.91348.58. Epub 2004 Feb 23.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
200065
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes
NCT04133922
WITHDRAWN
EARLY_PHASE1
The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis
NCT02765399
COMPLETED
PHASE4
Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease
NCT04057261
WITHDRAWN
PHASE3
The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes
NCT01595789
COMPLETED
PHASE4
Cardiovascular Effects of GLP-1 Receptor Activation
NCT03101930
COMPLETED
PHASE4
Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients
NCT01761318
COMPLETED
PHASE4
GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow
NCT01988545
UNKNOWN
NA
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
NCT01607450
COMPLETED
PHASE2/PHASE3
GLP-1 on Non-ST-Segment Elevation Myocardial Infarction
NCT02577848
UNKNOWN
NA
Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects
NCT02408705
COMPLETED
PHASE2
Blood Pressure Outcomes With Liraglutide Therapy
NCT01755572
COMPLETED
PHASE4
Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease
NCT04146155
UNKNOWN
PHASE4
The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans
NCT02403284
COMPLETED
PHASE4
Exercise and GLP-1 RA on Insulin Secretion
NCT04383197
UNKNOWN
NA
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
NCT01234649
COMPLETED
PHASE3
The Effect of Liraglutide on the GIT
NCT04008290
UNKNOWN
PHASE4
Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus
NCT01954147
UNKNOWN
PHASE1/PHASE2
GLP-1 and Hypoglycemia
NCT01858896
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects
NCT02147925
COMPLETED
PHASE4
Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists
NCT06818292
COMPLETED
NA
Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults
NCT02333591
COMPLETED
PHASE4
Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes
NCT02016846
UNKNOWN
PHASE3
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
NCT05780905
RECRUITING
PHASE4
GLP-1 and Non-exercise Activity Thermogenesis in RHZ
NCT01638260
TERMINATED
PHASE4
Glucose Variability in Subclinical Hypertrophy
NCT02748434
ACTIVE_NOT_RECRUITING
NA